Home

The Korea Herald

Latest news

Most Popular

  1. 1

    K-pop group's manager dismissed for setting up spycam in theater dressing room

    K-pop group's manager dismissed for setting up spycam in theater dressing room
  2. 2

    Contentious grain bill put directly to plenary meeting for vote

    Contentious grain bill put directly to plenary meeting for vote
  3. 3

    Will tug-of-war between doctors, government end soon?

    Will tug-of-war between doctors, government end soon?
  4. 4

    Climate impacts set to cut 2050 global GDP by nearly a fifth

    Climate impacts set to cut 2050 global GDP by nearly a fifth
  5. 5

    Yoon's approval rating plunges to all-time low

    Yoon's approval rating plunges to all-time low
  1. 6

    Trilateral talks acknowledge ‘serious’ slumps of won, yen

    Trilateral talks acknowledge ‘serious’ slumps of won, yen
  2. 7

    [Today’s K-pop] BTS pop-up event to come to Seoul

    [Today’s K-pop] BTS pop-up event to come to Seoul
  3. 8

    [Graphic News] More Koreans say they plan long-distance trips this year

    [Graphic News] More Koreans say they plan long-distance trips this year
  4. 9

    [KH Explains] Hyundai's full hybrid edge to pay off amid slow transition to pure EVs

    [KH Explains] Hyundai's full hybrid edge to pay off amid slow transition to pure EVs
  5. 10

    North Korea removes streetlights along cross-border roads with South

    North Korea removes streetlights along cross-border roads with South
소아쌤

Samsung BioLogics resumes stalled biosimilar project

By 황유미

Published : Aug. 2, 2016 - 16:06

    • Link copied

[THE INVESTOR] Archigen Biotech, a 50:50 joint venture between Samsung BioLogics and Astrazeneca UK established in 2014, has recently resumed its stalled biosimilar development project. 

According to industry sources on Aug. 2, the company has applied for US Food and Drug Administration’s approval to initiate phase 1 of clinical trials for SAIT101 in June.


A Samsung BioLogics plant in Songdo, Incheon A Samsung BioLogics plant in Songdo, Incheon


SAIT101 is a biosimilar version of rituximab, more commonly known as Roche’s Rituxan, used to treat non-Hodgkin’s lymphoma and autoimmune diseases. Also known as MabThera in South Korea and Europe, it is among the top five biological drugs sold worldwide, reaching US$7.3 billion in annual sales last year. Rituxan’s patent in US expires in 2018.

“Samsung’s bio businesses have two axis, CMO under BioLogics and biosimilar development under Bioepis, but with this it is strengthening the development sector,” an industry source said adding that “it can be understood as a step to expanding itself in the bio industry.”

By Hwang You-mee (glamazon@heraldcorp.com)

More from Headlines